MedTrace Logo

TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis

NCT00023426 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2005-09-13

No results posted yet for this study

Summary

Randomized, double-blind study of the tolerability of three different doses of rifapentine

Conditions

Interventions

DRUG

rifapentine

Sponsors & Collaborators

Principal Investigators

  • Naomi Bock, MD · Centers for Disease Control & Prevention

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Completion
2003-02-28

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00023426 on ClinicalTrials.gov